Valuation: OliX Pharmaceuticals, Inc

Market Cap 2,214B 1.67B 1.5B 1.38B 1.25B 2.34B 158B 2.37B 16.58B 6.58B 83.07B 6.26B 6.13B 263B P/E 2026 *
-62.9x
P/E 2027 * -64.7x
Enterprise Value 2,214B 1.67B 1.5B 1.38B 1.25B 2.34B 158B 2.37B 16.58B 6.58B 83.07B 6.26B 6.13B 263B EV / Sales 2026 *
277x
EV / Sales 2027 * 201x
Free-Float
84.88%
Yield 2026 *
-
Yield 2027 * -
10-13 Roche Licenses Obesity Therapy From China's Rona in Up to $1.2 Billion Deal DJ
08-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-30 OliX Pharmaceuticals, Inc Reports Preclinical Data Demonstrating Greater Visceral Fat Reduction with Olx501a Versus Global Comparator in Obese Non-Human Primates CI
07-08 OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-29 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
06-01 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-01 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-08 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-02 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
1 day-5.72%
1 week-7.17%
Current month-11.61%
1 month-11.78%
3 months-20.32%
6 months-53.89%
Current year-35.47%
1 week 86,600
Extreme 86600
109,600
1 month 84,300
Extreme 84300
126,900
Current year 84,300
Extreme 84300
217,000
1 year 84,300
Extreme 84300
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 01/02/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 28/03/2022
Director TitleAgeSince
Director/Board Member 61 19/03/2019
Director/Board Member 55 19/03/2019
Chairman 54 01/02/2010
Date Insider Type Main position Quantity % Market Cap. Importance
2/28/25 A Exercice

Director

30,000 0.1625%
2/28/25 A Exercice

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
-5.72%-7.17%-9.13%+583.77% 1.55B
+0.65%-3.56%+33.53%+60.50% 63.48B
+2.32%+1.78%+12.38%+83.04% 54.55B
-0.91%+0.83%+10.28%+101.86% 53.59B
+3.32%+1.74%+29.02%+58.86% 44.75B
+2.38%-2.99%+18.33%+100.91% 41.62B
+0.67%-3.26%+223.10%+924.25% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+26.24%+43.24%+100.96%+88.50% 26.7B
+3.72%-6.23%+26.01%-8.28% 23.36B
Average +3.16%-2.12%+45.55%+203.81% 38.2B
Weighted average by Cap. +2.97%-0.54%+47.04%+162.52%

Financials

2026 *2027 *
Net sales 8B 6.03M 5.41M 5M 4.53M 8.47M 573M 8.57M 59.91M 23.79M 300M 22.63M 22.15M 952M 11B 8.29M 7.44M 6.87M 6.23M 11.64M 788M 11.79M 82.38M 32.72M 413M 31.12M 30.46M 1.31B
Net income -31B -23.37M -20.97M -19.36M -17.56M -32.82M -2.22B -33.22M -232M -92.2M -1.16B -87.71M -85.83M -3.69B -30B -22.61M -20.29M -18.74M -16.99M -31.76M -2.15B -32.15M -225M -89.22M -1.13B -84.88M -83.06M -3.57B
Net Debt - -
Projected Income Statement - Annual - OliX Pharmaceuticals, Inc
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
81
Date Price Change Volume
28/10/26 ₩97,300.00 +7.40% 224,874
27/10/26 ₩90,600.00 -5.72% 260,316
26/10/26 ₩96,100.00 -6.97% 103,794
23/10/26 ₩103,300.00 -2.18% 123,994
22/10/26 ₩105,600.00 -1.22% 127,964
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - OliX Pharmaceuticals, Inc

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - OliX Pharmaceuticals, Inc
  1. Stock Market
  2. Stocks
  3. A226950 Stock